Catalyst Wire Dossier Catalyst Wire Dossier

SHP681

GLP-2 analog-Fc fusion · Shire
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SHP681, covering 2021-02-25 to 2021-02-25. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending, Subcutaneous, Single and Multiple Doses of SHP681 (Glucagon-like Peptide-2 [GLP-2] Analog-Fc Fusion) in Healthy Adult Participants [Phase 1]

See pricing